BioCentury | Sep 30, 2020
Deals

As China’s CStone preps for launches, Pfizer buys equity stake and local rights to PD-L1 program

...programs in-licensed from the West, such as targeted oncology therapies Ayvakit avapritinib and Gavreto pralsetinib from Blueprint Medicines Corp....
BioCentury | Sep 5, 2020
Product Development

With second approval of year, Blueprint readies to put partner Genentech into play

...acquire Loxo. FDA approved Gavreto pralsetinib from Blueprint Medicines Corp....
...as well as EMA review in NSCLC. Amanda Micklus Blueprint Medicines Corp. Genentech...
BioCentury | Sep 2, 2020
Management Tracks

Namouni to lead Blueprint R&D; plus Davar to head R&D at Acadia, Napolitano replaces Burow on Vir’s board, and more

...By Sandi Wong, Assistant Editor Precision cancer therapy play Blueprint Medicines Corp. (NASDAQ:BPMC) hired Fouad Namouni as president of...
...organization’s CSO and EVP for the past 10 years. BC Staff Acadia Pharmaceuticals Inc. Nocion Therapeutics Inc. Indapta Therapeutics Inc. Blueprint Medicines Corp. Sparx...
BioCentury | Jul 25, 2020
Finance

Preclinical IPOs attracting big money, but yet to see exponential growth of clinical peers

...all of them have generated substantial market cap gains, with Agios Pharmaceuticals Inc. (NASDAQ:AGIO) and Blueprint Medicines Corp....
BioCentury | Jul 24, 2020
Regulation

Data Bytes: CHMP’s July recommendations

...GSK137173A, hz/su, Herpes zoster vaccine) Swedish Orphan Biovitrum AB Stemline Therapeutics Inc. GlaxoSmithKline plc AstraZeneca plc Adheron Therapeutics Inc. Gilead Sciences Inc. Blueprint Medicines Corp. Insmed...
BioCentury | Jul 21, 2020
Product Development

Vaccine hopes, the shifting biopharma workplace & Blueprint’s Dx deal: a BioCentury Podcast

...is Done” ). Associate Editor Stephen Hansen analyzes the year’s largest licensing deal thus far. Blueprint Medicines Corp....
...see “Roche Deal Clears Path for Blueprint’s Financial Independence” ). Jeff Cranmer, Executive Editor University of Oxford AstraZeneca plc Blueprint Medicines podcast covid-19 cov19count chs2020 cov19count...
BioCentury | Jul 17, 2020
Finance

Data Bytes: preclinical IPO performance trending up

...NASDAQ:CRSP), at 425%; bispecific mAb company IGM Biosciences Inc. (NASDAQ:IGMS), at 356%; precision cancer company Blueprint Medicines Corp....
BioCentury | Jul 14, 2020
Deals

Roche deal clears path for Blueprint’s financial independence

...a precision oncology therapy targeting RET. Via the companies’ deal to develop and commercialize pralsetinib, Blueprint Medicines Corp....
...Ret proto-oncogene ROS1 - C-ros proto-oncogene 1 receptor tyrosine kinase Stephen Hansen, Associate Editor pralsetinib (BLU-667, CS3009) Blueprint Medicines Corp. Roche...
BioCentury | Jun 20, 2020
Management Tracks

Nurix bolsters leadership; plus Lynch named Xilio chairman, Edgewise, BioXCel, Catabasis, Catalyst and more

...adviser at Third Rock Ventures and chairs bluebird bio Inc. (NASDAQ:BLUE), Surface Oncology Inc. (NASDAQ:SURF), Blueprint Medicines Corp....
BioCentury | May 30, 2020
Product Development

May 29 ASCO Quick Takes: Investors sour on Arvinas’ targeted degraders; plus MacroGenics, Karyopharm, Blueprint

...NSCLC data support Blueprint’s regulatory filing for RET inhibitor pralsetinib Registrational data for pralsetinib from Blueprint Medicines Corp....
...RET - Ret proto-oncogene XPO1 (CRM1) - Exportin 1 BioCentury Staff pralsetinib (BLU-667, CS3009) Karyopharm Therapeutics Inc. MacroGenics Inc. Arvinas Inc. Blueprint Medicines Corp. Epidermal...
Items per page:
1 - 10 of 161
BioCentury | Sep 30, 2020
Deals

As China’s CStone preps for launches, Pfizer buys equity stake and local rights to PD-L1 program

...programs in-licensed from the West, such as targeted oncology therapies Ayvakit avapritinib and Gavreto pralsetinib from Blueprint Medicines Corp....
BioCentury | Sep 5, 2020
Product Development

With second approval of year, Blueprint readies to put partner Genentech into play

...acquire Loxo. FDA approved Gavreto pralsetinib from Blueprint Medicines Corp....
...as well as EMA review in NSCLC. Amanda Micklus Blueprint Medicines Corp. Genentech...
BioCentury | Sep 2, 2020
Management Tracks

Namouni to lead Blueprint R&D; plus Davar to head R&D at Acadia, Napolitano replaces Burow on Vir’s board, and more

...By Sandi Wong, Assistant Editor Precision cancer therapy play Blueprint Medicines Corp. (NASDAQ:BPMC) hired Fouad Namouni as president of...
...organization’s CSO and EVP for the past 10 years. BC Staff Acadia Pharmaceuticals Inc. Nocion Therapeutics Inc. Indapta Therapeutics Inc. Blueprint Medicines Corp. Sparx...
BioCentury | Jul 25, 2020
Finance

Preclinical IPOs attracting big money, but yet to see exponential growth of clinical peers

...all of them have generated substantial market cap gains, with Agios Pharmaceuticals Inc. (NASDAQ:AGIO) and Blueprint Medicines Corp....
BioCentury | Jul 24, 2020
Regulation

Data Bytes: CHMP’s July recommendations

...GSK137173A, hz/su, Herpes zoster vaccine) Swedish Orphan Biovitrum AB Stemline Therapeutics Inc. GlaxoSmithKline plc AstraZeneca plc Adheron Therapeutics Inc. Gilead Sciences Inc. Blueprint Medicines Corp. Insmed...
BioCentury | Jul 21, 2020
Product Development

Vaccine hopes, the shifting biopharma workplace & Blueprint’s Dx deal: a BioCentury Podcast

...is Done” ). Associate Editor Stephen Hansen analyzes the year’s largest licensing deal thus far. Blueprint Medicines Corp....
...see “Roche Deal Clears Path for Blueprint’s Financial Independence” ). Jeff Cranmer, Executive Editor University of Oxford AstraZeneca plc Blueprint Medicines podcast covid-19 cov19count chs2020 cov19count...
BioCentury | Jul 17, 2020
Finance

Data Bytes: preclinical IPO performance trending up

...NASDAQ:CRSP), at 425%; bispecific mAb company IGM Biosciences Inc. (NASDAQ:IGMS), at 356%; precision cancer company Blueprint Medicines Corp....
BioCentury | Jul 14, 2020
Deals

Roche deal clears path for Blueprint’s financial independence

...a precision oncology therapy targeting RET. Via the companies’ deal to develop and commercialize pralsetinib, Blueprint Medicines Corp....
...Ret proto-oncogene ROS1 - C-ros proto-oncogene 1 receptor tyrosine kinase Stephen Hansen, Associate Editor pralsetinib (BLU-667, CS3009) Blueprint Medicines Corp. Roche...
BioCentury | Jun 20, 2020
Management Tracks

Nurix bolsters leadership; plus Lynch named Xilio chairman, Edgewise, BioXCel, Catabasis, Catalyst and more

...adviser at Third Rock Ventures and chairs bluebird bio Inc. (NASDAQ:BLUE), Surface Oncology Inc. (NASDAQ:SURF), Blueprint Medicines Corp....
BioCentury | May 30, 2020
Product Development

May 29 ASCO Quick Takes: Investors sour on Arvinas’ targeted degraders; plus MacroGenics, Karyopharm, Blueprint

...NSCLC data support Blueprint’s regulatory filing for RET inhibitor pralsetinib Registrational data for pralsetinib from Blueprint Medicines Corp....
...RET - Ret proto-oncogene XPO1 (CRM1) - Exportin 1 BioCentury Staff pralsetinib (BLU-667, CS3009) Karyopharm Therapeutics Inc. MacroGenics Inc. Arvinas Inc. Blueprint Medicines Corp. Epidermal...
Items per page:
1 - 10 of 161